A teenage girl faced with sudden rapid heart deterioration, a man in the prime years of his life suffering from debilitating heart failure and a former NFL athlete crippled by end-stage heart failure were all successfully treated with a surgical approach pioneered by cardiac experts at University of California, San Diego School of Medicine.
The work demonstrated significant benefits of implanting a left ventricular assist device (LVAD) in the right atrium to provide better blood flow through the lungs, giving complete biventricular circulatory support and fully replacing the heart’s function.
An LVAD is a small mechanical pump traditionally placed inside the left ventricle – one of four chambers of the heart, located in the lower left of the organ – to help restore blood flow throughout the body. Unlike an artificial heart, the LVAD doesn’t replace the heart, but it can mean the difference between life and death for a person waiting for a transplant or suffering from advanced heart failure.
‘An LVAD relieves symptoms, such as being constantly tired or short of breath in patients with advanced heart disease,’ said Victor Pretorius, MBchB, lead author of the report and surgical director of cardiac transplant and mechanical circulatory support at UC San Diego Health. ‘The caveat is that the LVAD still depends on the right side of the patient’s heart to function optimally, and right ventricle failure is a common condition after an LVAD implantation, leaving some patients only partially treated. It is difficult to predict and increases mortality.’
Pretorius said biventricular support is required for up to 30 percent of LVAD recipients. Currently, no durable, long-term right ventricular assist device (RVAD) has received Food and Drug Administration approval, and placing an LVAD in the right ventricle, for which it was not designed, may jeopardize the device and heart function.
‘An alternative strategy would be to remove the heart completely and replace it with a total artificial heart, but this strategy does not allow for the failing heart to potentially recover, and there is the risk of the device malfunctioning,’ said Pretorius. ‘All three patients involved in the study were in desperate need of right-sided circulatory support. Our team placed an additional HeartWare HVAD, the smallest available LVAD, in the right atrium, the upper chamber of the heart, to provide right heart support.’
The right atrium is considered a more ideal chamber for placing a mechanical pump to support right-sided circulation. The absence of valve structures ensures unobstructed blood flow into the pump, and the location next to the right lung makes accommodation for the pump’s motor in the chest cavity more feasible.
An LVAD is composed of a computer controller, a power pack and a reserve power pack that remain outside the body and are recharged at night. Patients with the innovative BiVAD approach have to carry a duplicate set for each pump, but Pretorius said this is generally well tolerated.
Two of three patients in the study received successful heart transplants after receiving right-sided circulatory support, and the third patient remains in good condition with both LVADs still implanted.

University San Diego Healthhttp://tinyurl.com/zsjjwuh

University of Miami Miller School of Medicine researchers have found a link between

Pancreatic cancer is the third leading cause of cancer deaths in the United States, in part because it is very difficult for chemotherapy drugs to reach the pancreas, which is located deep within the abdomen.

To help overcome that obstacle, researchers from MIT and Massachusetts General Hospital have now developed a small, implantable device that delivers chemotherapy drugs directly to pancreatic tumours. In a study of mice, they found that this approach was up to 12 times more effective than giving chemotherapy drugs by intravenous injection, which is how most pancreatic cancer patients are treated.

Stem cells that have been specifically developed for use as clinical therapies are fit for use in patients, scientists have found.  The research focused on human embryonic stem cells.  It paves the way for clinical trials of cell therapies to treat conditions such as Parkinson

The most commonly performed operation in the world is cesarean section, and rates of cesarean childbirth delivery vary widely from country to country, from as little as 2 percent to more than 50 percent of live births. The World Health Organization recommends countries not exceed 10 to 15 percent (10 to 15 C-section deliveries per 100 live births) for optimal maternal and neonatal outcomes.
However, new research examining the relationship between C-section rates and maternal and neonatal mortality in 194 countries concludes that as the country-level C-section rate increases up to 19 percent, maternal and neonatal mortality rates decline. C-section delivery rates above 19 percent showed no further improvement in maternal and neonatal mortality rates.
Researchers from Ariadne Labs, a joint centre of Brigham and Women